| Literature DB >> 24349588 |
María Belén Pisano1, Griselda Oria2, Geraldine Beskow2, Javier Aguilar1, Brenda Konigheim1, María Luisa Cacace3, Luis Aguirre4, Marina Stein2, Marta Silvia Contigiani1.
Abstract
Venezuelan equine encephalitis viruses (VEEV) are responsible for human diseases in the Americas, producing severe or mild illness with symptoms indistinguishable from dengue and other arboviral diseases. For this reason, many cases remain without certain diagnosis. Seroprevalence studies for VEEV subtypes IAB, ID, IF (Mosso das Pedras virus; MDPV), IV (Pixuna virus; PIXV) and VI (Rio Negro virus; RNV) were conducted in persons from Northern provinces of Argentina: Salta, Chaco and Corrientes, using plaque reduction neutralization test (PRNT). RNV was detected in all studied provinces. Chaco presented the highest prevalence of this virus (14.1%). Antibodies against VEEV IAB and -for the first time- against MDPV and PIXV were also detected in Chaco province. In Corrientes, seroprevalence against RNV was 1.3% in the pediatric population, indicating recent infections. In Salta, this was the first investigation of VEEV members, and antibodies against RNV and PIXV were detected. These results provide evidence of circulation of many VEE viruses in Northern Argentina, showing that surveillance of these infectious agents should be intensified.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24349588 PMCID: PMC3861189 DOI: 10.1371/journal.pntd.0002551
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Figure 1Map of Argentina.
Provinces evaluated in this study and provinces where VEEVs have previously been detected.
Positive samples for antibody detection against VEEV IAB, PIXV (IV) and RNV (VI) in humans from Chaco province and their titers during 2007.
| Virus | ||||||
| Sample N° | VEEV-IAB | RNV | PIXV | Age | Sex | Place |
| 41 | − | + (≥640) | + (20) | 20 | F | Cap. Solari |
| 43 | − | + (40) | − | 3 | F | R |
| 44 | + (20) | + (320) | + (20) | 20 | F | R |
| 51 | − | + (40) | − | 21 | F | R |
| 99 | − | + (160) | − | 5 | M | R |
| 194 | − | + (80) | − | 19 | F | R |
| 290 | + (80) | + (2560) | + (160) | 14 | M | R |
| 295 | + (80) | + (2560) | + (160) | 21 | F | Cap. Solari |
| 344 | − | + (160) | − | 17 | F | R |
| 369 | + (80) | + (1280) | + (80) | 21 | F | R |
| 382 | + (20) | + (>640) | + (80) | 26 | F | R |
| 395 | + (10) | + (320) | + (80) | 38 | M | R |
| 408 | + (10) | + (640) | + (80) | 38 | F | R |
| 432 | + (10) | + (>640) | − | 28 | M | Fontana |
| 444 | − | + (640) | + (10) | 23 | M | R |
| 460 | + (40) | + (640) | + (40) | 41 | M | Fontana |
| 474 | − | + (>640) | − | 52 | F | R |
| 485 | − | + (80) | − | 51 | F | Fontana |
| 524 | + (20) | + (640) | + (40) | 23 | F | El Sauzalito |
| 541 | + (40) | + (>640) | + (20) | 32 | M | R |
| 555 | + (20) | + (320) | + (20) | 29 | F | R |
| 567 | + (20) | + (160) | + (20) | 30 | M | R |
| 570 | + (20) | + (>640) | + (10) | 26 | F | Barranqueras |
+: positive; −: negative.
Age (years):
F: female; M: male.
R: Resistencia.
Cross reactions between VEEV IAB, VEEV ID, MDPV (IF), PIXV (IV) and RNV (VI) by PRNT (15).
| Mouse | immune | ascitic | fluid | against: | |
| Virus/Subtype | VEEV-IAB | VEEV-ID | MDPV-IF | PIXV-IV | RNV-VI |
|
| + | − | − | +/− | − |
|
| − | + | − | − | − |
|
| +/− | +/− | + | +/− | − |
|
| +/− | − | − | + | +/− |
|
| − | +/− | − | +/− | + |
+: Titer ≥320.
+/−: Titer between 10 and 40.
−: Titer <10.
Positive samples for detection of neutralizing Abs against VEEV IAB, MDPV (IF), PIXV (IV) and RNV (VI), and their titers in Pampa del Indio (Chaco Province) in the period December 2010–May 2011.
| Virus | |||||
| Sample N° | VEEV-IAB | MDPV | RNV | PIXV | Sex |
| 2 | − | + (20) | + (20) | + (10) | F |
| 3 | + (20) | − | + (80) | + (20) | M |
| 6 | − | + (40) | + (80) | + (20) | F |
| 8 | − | + (10) | + (20) | + (10) | F |
| 9 | − | + (20) | + (40) | + (10) | F |
| 10 | − | + (10) | + (80) | + (10) | F |
| 16 | + (20) | + (20) | + (40) | + (40) | F |
| 17 | − | + (40) | + (40) | + (10) | M |
| 18 | − | + (10) | + (80) | + (10) | M |
| 23 | − | + (20) | + (20) | − | F |
| 25 | − | + (10) | + (40) | + (10) | M |
| 26 | − | + (40) | + (160) | + (10) | F |
| 27 | − | + (20) | + (20) | + (10) | M |
| 28 | − | + (20) | + (160) | + (20) | F |
| 31 | − | + (20) | + (20) | + (20) | M |
| 33 | + (20) | + (80) | + (160) | + (40) | F |
| 37 | − | − | + (40) | + (20) | F |
| 51 | − | + (20) | − | + (10) | F |
| 53 | − | + (20) | − | − | M |
| 57 | − | + (20) | + (20) | − | F |
| 59 | + (10) | + (20) | + (80) | + (10) | F |
| 61 | + (10) | + (40) | − | + (40) | F |
| 63 | + (10) | + (20) | + (80) | + (20) | F |
| 66 | + (10) | − | − | − | M |
| 78 | − | − | + (40) | − | F |
| 80 | + (80) | + (>320) | + (320) | + (80) | M |
| 81 | + (20) | + (80) | − | + (20) | M |
| 85 | + (20) | + (80) | + (20) | − | M |
| 86 | + (20) | + (20) | + (640) | + (40) | F |
| 87 | + (10) | + (10) | − | + (10) | M |
| 90 | + (10) | + (80) | − | + (40) | F |
| 93 | + (20) | + (40) | − | − | M |
| 94 | − | − | + (80) | − | M |
| 95 | + (10) | + (40) | + (160) | − | M |
| 99 | − | − | + (160) | − | M |
| 104 | − | − | + (320) | − | F |
| 109 | − | + (40) | + (80) | + (20) | F |
| 110 | − | − | + (160) | − | F |
| 112 | + (10) | + (20) | + (>640) | − | F |
| 115 | − | + (20) | + (160) | + (20) | M |
| 116 | − | − | + (80) | − | F |
| 123 | − | − | + (40) | + (10) | F |
+: positive; −: negative.
F: female; M: male.
Positive serum samples against VEEV IAB and RNV (VI) by PRNT from Corrientes Province obtained of pediatric patients (0–20 years old) between December 2006 and April 2007.
| Virus | |||||
| Sample N° | VEEV-IAB | RNV | Age (years) | Sex | Place |
| 197 | − | + (10) | 8 | M | Corrientes |
| 313 | + (20) | + (≥640) | 12 | F | Chaco |
| 326 | + (10) | + (≥640) | 10 | M | Corrientes |
+: positive −: negative.
F: female; M: male.
Detections of VEEV ID, PIXV (IV) and RNV (VI) by PRNT in samples from Orán, Salta Province, in 2009.
| Virus | |||||
| Sample N° | RNV | PIXV | VEEV-ID | Sex | Age (years) |
| 234 | + (80) | + (40) | − | M | 67 |
| 413 | + (10) | + (20) | − | F | 32 |
| 419 | + (20) | + (80) | − | M | 48 |
| 422 | + (40) | − | − | F | 21 |
| 619 | + (160) | + (10) | − | M | 49 |
+: positive. −: negative.
F: female; M: male.